Treatment outcomes of retinal vein occlusion in clinical practice in Nepal

Abstract Background This study evaluated the treatment outcomes of retinal vein occlusion (RVO) in a routine clinical practice Nepal. Methods was retrospective analysis observational data patients with RVO who attended retina clinic Tilganga Institute Ophthalmology from 1 November 2017 to 31 October 2018. The main outcome mean change visual acuity (VA) at 12 months start treatment. Other interest were central subfield thickness (CST) and number treatments over months. Results A total 99 eyes (of patients) (60 - branch [BRVO] 39 [CRVO] available for analysis. Eyes CRVO had worse VA CST baseline. both groups similar age, associated factors RVO, duration vision loss presence ischemia (95% Confidence Interval [CI]) BRVO − 0.35 (− 0.46, 0.23) logMAR ( p < 0.001) (SD) 0.75 (0.42) baseline 63% achieving 0.3 while it = 0.19) 1.13 (0.61) 36%. CI) 114 189, 40) μm 0.003) 423 (151) 184(− 276, 91) 519 (213) CRVO. Patients received median 2 bevacizumab injections Around 37% lost before months’ observation. trajectory these their last visit those that completed Conclusion inferior fewer than trials other reports practice. Future studies identify barriers are warranted improve our patients.